NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company was founded by Mitchell Rubenstein and Laurie S. Silvers on January 22, 1993 and is headquartered in Boca Raton, FL.